Approved glycopeptide antibacterial drugs: Mechanism of action and resistance

Document Type

Article

Publication Date

1-1-2016

Abstract

The glycopeptide antimicrobials are a group of natural product and semisynthetic glycosylated peptides that show antibacterial activity against Gram-positive organisms through inhibition of cell-wall synthesis. This is achieved primarily through binding to the Dalanyl- D-alanine terminus of the lipid II bacterial cell-wall precursor, preventing crosslinking of the peptidoglycan layer. Vancomycin is the foundational member of the class, showing both clinical longevity and a still preferential role in the therapy of methicillinresistant Staphylococcus aureus and of susceptible Enterococcus spp. Newer lipoglycopeptide derivatives (telavancin, dalbavancin, and oritavancin) were designed in a targeted fashion to increase antibacterial activity, in some cases through secondary mechanisms of action. Resistance to the glycopeptides emerged in delayed fashion and occurs via a spectrum of chromosome- and plasmid-associated elements that lead to structural alteration of the bacterial cell-wall precursor substrates.

Publication Title

Cold Spring Harbor Perspectives in Medicine

DOI

10.1101/cshperspect.a026989

This document is currently not available here.

Share

COinS